Journal: bioRxiv

Article Title: Macrophages regulate meiotic initiation and germ cell clearance in the developing ovary

doi: 10.64898/2026.02.28.708733

Figure Lengend Snippet: (a) Representative whole-mount images of E13.5 ovaries from C57BL/6J embryos exposed at E6.5 to either control rat IgG2a antibody or anti-CSF1R blocking antibody to deplete YS-derived macrophages. For F4/80, PECAM1, and FOXL2 staining, n =5 control and n =6 anti-CSF1R-treated independent gonads; for CD11b and CD45 staining, n =3 control and n =3 anti-CSF1R-treated independent gonads. Insets show higher-magnification views of boxed regions; dashed lines mark the gonad-mesonephros boundary. (b) qRT-PCR analysis of macrophage-associated genes ( Adgre1, Cx3cr1, Csf1r, Mrc1 ) and endothelial marker Cdh5 , showing fold change in gene expression in E13.5 anti-CSF1R-treated ovaries versus controls. (c) Representative E14.5 sections stained for SYCP3 and TRA98 showing increased meiotic germ cells in anti-CSF1R-treated ovaries ( n =4) compared with control ovaries ( n =4). (d) qRT-PCR analysis of germ cell and meiotic genes ( Kit, Pou5f1, Ddx4, Stra8, Sycp1, Sycp3, Syce1, Smc1b ), showing fold change in gene expression in E14.5 anti-CSF1R-treated ovaries versus controls. (e) Representative E18.5 sections stained for F4/80 and CD45, and for SYCP3 and FOXL2, showing recovery of F4/80⁺ macrophages and advanced meiotic progression in anti-CSF1R-treated ovaries compared with control ovaries. For F4/80 and CD45 staining, n =4 control and n =4 anti-CSF1R-treated independent gonads; for SYCP3 and FOXL2 staining, n =3 control and n =3 anti-CSF1R-treated independent gonads. Arrows indicate SYCP3⁺ dictyate-stage oocytes. (f) Percentage of SYCP3⁺ germ cells at the dictyate stage among total SYCP3⁺ cells at E18.5. Data are shown as mean +/− SD. * P <0.05, ** P <0.01, *** P <0.001 (two-tailed Student’s t -tests). Scale bars, 100 μm (overview) and 50 μm (higher magnification/insets).

Article Snippet: To transiently deplete yolk-sac-derived and fetal CSF1R + macrophages, pregnant C57BL/6J females were injected intraperitoneally with 3 mg anti-CSF1R monoclonal antibody (mAb; clone AFS98, Bio X Cell #BP0213) or rat IgG2a isotype control (Bio X Cell #BP0089).

Techniques: Control, Blocking Assay, Derivative Assay, Staining, Quantitative RT-PCR, Marker, Gene Expression, Two Tailed Test

Journal: bioRxiv

Article Title: Macrophages regulate meiotic initiation and germ cell clearance in the developing ovary

doi: 10.64898/2026.02.28.708733

Figure Lengend Snippet: (a) Representative images of E18.5, P3, and P10 ovaries from C57BL/6J embryos exposed at E6.5 and E14.5 to either control rat IgG2a antibody or anti-CSF1R blocking antibody to deplete fetal ovarian macrophages. For E18.5, n =4 control and n =4 anti-CSF1R-treated independent gonads; for P3, n =6 control and n =6 anti-CSF1R-treated independent gonads; for P10, n =4 control and n =4 anti-CSF1R-treated independent gonads. Insets show higher-magnification views of boxed regions; red and green dashed outlines demarcate the ovary. (b) Representative sections stained for DDX4, showing developmental germ cell attrition at E18.5, P3, and P10 in control and anti-CSF1R-treated ovaries. For each time point, n =4 control and n =4 anti-CSF1R-treated independent gonads. (c) Quantification of CD45⁺IBA1 + macrophages per 0.1 mm² ovarian area at E18.5, P3, and P10. (d) Quantification of CD45⁺IBA1 − monocyte-like cells per 0.1 mm² ovarian area at the indicated stages. (e) Quantification of DDX4⁺ germ cell number per 0.1 mm² ovarian area at E18.5, P3, and P10, showing reduced physiological germ cell loss after macrophage depletion. Data are shown as mean +/− SD. * P <0.05, ** P <0.01, *** P <0.001 (two-tailed Student’s t -tests). Scale bars, 100 μm (overview) and 50 μm (higher magnification/insets).

Article Snippet: To transiently deplete yolk-sac-derived and fetal CSF1R + macrophages, pregnant C57BL/6J females were injected intraperitoneally with 3 mg anti-CSF1R monoclonal antibody (mAb; clone AFS98, Bio X Cell #BP0213) or rat IgG2a isotype control (Bio X Cell #BP0089).

Techniques: Control, Blocking Assay, Staining, Two Tailed Test

Journal: Cell

Article Title: Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

doi: 10.1016/j.cell.2017.04.014

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Ant-Human PD-L1 (clone 29E.2A3) -175Lu , Fluidigm , Cat#: 3175017B.

Techniques: Recombinant, Labeling, Expressing, Gene Expression, Sequencing, Software

Journal: Cell

Article Title: Single-cell Map of Diverse Immune Phenotypes in the Breast Tumor Microenvironment

doi: 10.1016/j.cell.2018.05.060

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Biological Samples Breast carcinoma Fresh operative tissue samples at MSKCC N/A Normal breast tissue Fresh operative tissue samples at MSKCC N/A Lymph node Fresh operative tissue samples at MSKCC N/A Peripheral blood Patient venipuncture at MSKCC N/A Antibodies anti-CD45 ab Biolegend RRID:AB_2566372 DAPI Stain Calbiochem SCR_014366 anti-Foxp3 ab Thermo Fisher RRID:AB_1834364 anti-CD3 ab Biolegend RRID:AB_1575008 anti-CD4 ab Biolegend RRID:AB_571945 anti-CD16 ab Biolegend RRID:AB_314207 anti-CD56 ab BD Biosciences RRID:AB_396853 anti-CD8 ab Biolegend RRID:AB_528885 anti-CD19 ab Biolegend RRID:AB_2562015 anti-CD11b ab Biolegend RRID:AB_2563395 anti-CD45 Y89 Fluidigm RRID:AB_2261851 anti-CD235ab BioLegend RRID:AB_314620 anti-CD61 BioLegend RRID:AB_1227584 anti-CD196/CCR6 Pr141 Fluidigm Cat:3141014A anti-CD19 142Nd Fluidigm RRID:AB_2651155 anti-CD278/ICOS 143Nd Fluidigm Cat:3143025B anti-CD270 144Nd Fluidigm Cat:3144022B anti-CD4 145Nd Fluidigm RRID:AB_2661789 anti-CD8a 146Nd Fluidigm Cat:3146001B anti-CD11c 147Sm Fluidigm RRID:AB_2687850 anti-CD14 148Nd Fluidigm Cat:3148010B anti-CD127 149Sm Fluidigm RRID:AB_2661792 anti-TIGIT eBioscience Cat:16-9500-82 anti-CD123 151Eu Fluidigm RRID:AB_2661794 anti-CD95/Fas 152Sm Fluidigm Cat:3152017B anti-CD45RA 153Eu Fluidigm Cat:3153001B anti-TIM3 154Sm Fluidigm Cat:3154010B anti-CD39 BioLegend RRID:AB_940438 anti-CD274/PD-L1 156Gd Fluidigm Cat: 3156026B anti-CD27 158Gd Fluidigm Cat: 3158010B anti-CD357/GITR 159Tb Fluidigm Cat: 3159020B anti-CD28 160Gd Fluidigm Cat: 3160003B anti-CD152/CTLA4 161Dy Fluidigm Cat: 3161004B anti-FoxP3 162Dy Fluidigm RRID:AB_2687650 anti-CD33 163Dy Fluidigm RRID:AB_2687857 anti-CD45RO 164Dy Fluidigm Cat: 3164007B anti-CD223/LAG3 165Ho Fluidigm RRID:AB_2687859 anti-Ki67 BD RRID:AB_396287 anti-CD197/CCR7 167Er Fluidigm Cat:3167009A anti-CD154/CD40L 168Er Fluidigm Cat: 3170011B anti-CD25 169Tm Fluidigm RRID:AB_2661806 anti-CD3 170Er Fluidigm RRID:AB_2661807 anti-CD226 171Tb Fluidigm Cat: 3171013B anti-CD38 172Yb Fluidigm Cat: 3172007B anti-CD137/4–1BB 173Yb Fluidigm Cat: 3173015B anti-CD279/PD-1 174Yb Fluidigm Cat: 3174020B anti-CD194/CCR4 175Lu Fluidigm Cat: 3175021A anti-CD56 176Yb Fluidigm RRID:AB_2661813 anti-CD11b 209Bi Fluidigm Cat: 3209003B Critical Commercial Assays inDrop platform Custom-built droplet microfluidics platform; Klein et al., 2015 ; Zilionis et al., 2017 .

Techniques: Staining, Antibody Labeling, Software, Diffusion-based Assay